论文部分内容阅读
纽约血液中心近日公布的一项研究报告显示,在562名白血球过多症、淋巴腺癌、其它癌症或遗传性疾病的患者中,在使用胎盘血液后,存活率与移植他人骨髓的患者差不多。而且在许多病例中,胎盘血液并未与患者的组织吻合,有别于骨髓捐赠者必须和接受者在组织分类测试中高度吻合。中心免疫遗传学主任巴布罗·鲁宾斯坦指出:胎盘血液最大的好处是,它不像骨髓需要与接受者的组织高达吻合。这代表它能协
A study published recently by the New York Blood Center showed that in 562 patients with leukemia, lymphoma, other cancers, or hereditary diseases, after using placental blood, the survival rate is similar to that of patients transplanted with other people’s bone marrow. And in many cases, placental blood does not match the patient’s tissue, unlike bone marrow donors who must be highly consistent with recipients in tissue classification tests. The director of the Center for Immunogenetics, Barber Rubinstein, pointed out that the greatest benefit of placental blood is that it does not resemble bone marrow and the recipient’s tissues. This means that it can